Journey Medical CorporationDERMNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -57.64% | -10.73% | +0.84% | +1.04% | +20.52% |
| Gross Profit Growth | -66.76% | +23.17% | +34.36% | +8.32% | +27.10% |
| EBITDA Growth | -104.42% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -116.78% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -114.24% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -113.19% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -115.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +11.52% | +14.64% | +14.44% | +16.49% | +21.53% |
| Weighted Average Shares Diluted Growth | -2.36% | +14.64% | +14.44% | +16.49% | +21.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -106.17% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -106.17% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +33.57% | -32.79% | +83.95% | +49.49% | +68.52% |
| Inventory Growth | +6.93% | +41.40% | +18.11% | +32.67% | +0.25% |
| Asset Growth | -2.84% | +4.41% | +27.63% | +24.50% | +33.02% |
| Book Value per Share Growth | -43.61% | -13.98% | +45.34% | +46.27% | +95.04% |
| Debt Growth | +15029.01% | +44.98% | +41.64% | +10.83% | +27.66% |
| R&D Expense Growth | -62.23% | -85.51% | -99.51% | -100.00% | -65.91% |
| SG&A Expenses Growth | +31.96% | +2.23% | +25.52% | +15.05% | -100.00% |